Hepatitis C Seroprevalence among Prison Inmates since 2001: Still High but Declining

• Published in: Public health reports (1974) Vol. 129; no. 2; pp. 187 - 195
• Main Authors: Varan, Aiden K., Mercer, Daniel W., Stein, Matthew S., Spaulding, Anne C.
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.03.2014; SAGE PUBLICATIONS, INC; Association of Schools of Public Health
• Subjects: Adult; Correctional institutions; Correctional treatment programs; Cost benefit analysis; Epidemics; Female; Health policy; Health risk assessment; Hepatitis; Hepatitis C; Hepatitis C - epidemiology; Hepatitis C - etiology; Humans; Implementation; Imprisonment; Male; Measurement; Population; Population number; Populations; Prisoners; Prisoners - statistics & numerical data; Prisons; Public health; Risk Factors; Seroepidemiologic Studies; Sex Distribution; States; Substance Abuse, Intravenous - complications; Surveillance; United States; United States - epidemiology; Upgrading; United States; United States > US
• ISSN: 0033-3549; 1468-2877
• DOI: 10.1177/003335491412900213

Objectives. Although the hepatitis C epidemic in the United States disproportionately affects correctional populations, the last national estimates of seroprevalence and disease burden among these populations are more than a decade old. We investigated routine hepatitis C surveillance conducted in state prison systems and updated previous estimates. Methods. We surveyed all U.S. state correctional departments to determine which state prison systems had performed routine hepatitis C screening since 2001. Using seroprevalence data for these prison systems, we estimated the national hepatitis C seroprevalence among prisoners in 2006 and the share of the epidemic borne by correctional populations. Results. Of at least 12 states performing routine testing from 2001 to 2012, seroprevalences of hepatitis C ranged from 9.6% to 41.1%. All but one state with multiple measurements demonstrated declining seroprevalence. We estimated the national state prisoner seroprevalence at 17.4% in 2006. Based on the estimated total U.S. correctional population size, we projected that 1,857,629 people with hepatitis C antibody were incarcerated that year. We estimated that correctional populations represented 28.5%–32.8% of the total U.S. hepatitis C cases in 2006, down from 39% in 2003. Conclusions. Our results provide an important updated estimate of hepatitis C seroprevalence and suggest that correctional populations bear a declining but still sizable share of the epidemic. Correctional facilities remain important sites for hepatitis C case finding and therapy implementation. These results may also assist future studies in projecting the societal costs and benefits of providing new treatment options in prison systems.